Skip to main content
SpringerLink
Log in

Spätfolgen onkologischer Therapie

Delayed effects of oncological therapy

  • CME Zertifizierte Fortbildung
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Spätschäden einer Krebserkrankung sind durch die therapiebedingt verbesserten Überlebensraten ein rasch zunehmendes, aber bislang zu wenig wahrgenommenes Problem. Zu diesen Folgeerkrankungen, die definitionsgemäß Jahre nach der initialen Erkrankung auftreten, zählen nicht nur Zweittumoren, sondern auch eine Reihe nichtonkologischer internistischer Probleme. Diese kardiovaskulären, gastrointestinalen, renalen oder endokrinen Spätschäden wurden bislang unzureichend beachtet und müssen bei der häufig schleichenden Symptomatik gezielt adressiert werden.

Abstract

Due to therapy-associated improvements in survival rates, delayed effects of cancer are a rapidly increasing but as yet only poorly recognized problem. These delayed sequelae, which by definition occur years after the primary disease, include secondary tumors and many non-oncological internal medical problems. Little attention has so far been paid to the cardiovascular, gastrointestinal, renal and endocrinal delayed side effects and must be specifically addressed due to the often slowly progressing symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Chemaitilly W, Sklar CA (2010) Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 17:R141–R159

    Article  PubMed  CAS  Google Scholar 

  2. Diller L, Chow EJ, Gurney JG et al (2009) Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 27:2339–2355

    Article  PubMed  Google Scholar 

  3. Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582

    Article  PubMed  CAS  Google Scholar 

  4. Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR (2012) Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 118(8 Suppl):2270–2276. doi:10.1002/cncr.27462. (Review. PubMed PMID: 22488701)

    Article  PubMed  Google Scholar 

  5. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25:72–85

    PubMed  CAS  Google Scholar 

  6. Adams MJ, Hardenbergh PH, Constine LS et al (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75

    Article  PubMed  Google Scholar 

  7. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ et al (1999) Ischemic heart disease after mantlefield irradiation for Hodgkin’s disease in long-term follow-up. Radiother Oncol 51:35–42

    Article  PubMed  CAS  Google Scholar 

  8. Travis LB, Beard C, Allan JM et al (2010) Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 102:1114–1130

    Article  PubMed  Google Scholar 

  9. Griffith ML, Savani BN, Boord JB (2010) Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 116:1197–1204

    Article  PubMed  CAS  Google Scholar 

  10. Bathia S, Constine LS (2009) Late morbidity after successful treatment of children with cancer. Cancer J 15:174–180

    Article  Google Scholar 

  11. Zhang Y, Goddard K, Spinelli JJ et al (2012) Risk of late mortality and second malignant neoplasms among 5-year survivors of young adult cancer: a report of the Childhood, Adolescent, and Young Adult Cancer Survivors Research Program. J Cancer Epidemiol 2012:103032

    PubMed  Google Scholar 

  12. Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. The Renal Insufficiency and Anticancer Medications (IRMA) Study. Cancer 110:1376–1384

    Article  PubMed  CAS  Google Scholar 

  13. Fosså SD, Aass N, Winderen M et al (2002) Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 13:222–228 (PubMed PMID: 11885998)

    Google Scholar 

  14. Skinner R (2011) Nephrotoxicity – what do we know and what don’t we know? J Pediatr Hematol Oncol 33:128–134

    Article  PubMed  Google Scholar 

  15. Goldsby R, Chen Y, Raber S et al (2011) Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology 140:1464.e1–1471.e1. doi:10.1053/j.gastro.2011.01.049 (Epub 2011 Mar 17 PubMed PMID: 21315721; PubMed Central PMCID: PMC3081911)

    Article  PubMed  Google Scholar 

  16. Andreyev HJ (2011) „Pelvic radiation disease“: new understanding and new solutions for a new disease in the era of cancer survivorship. Scand J Gastroenterol 46:389–397

    Article  PubMed  Google Scholar 

  17. Juszczak A, Gupta A, Karavitaki N et al (2012) Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 167:1–5

    Article  PubMed  CAS  Google Scholar 

  18. Darzy KH (2009) Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 5:88–99

    Article  PubMed  CAS  Google Scholar 

  19. Oberfield SE, Soranno D, Nirenberg A et al (1996) Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med 150:589–592

    Article  PubMed  CAS  Google Scholar 

  20. Ellison DH, Berl T (2007) Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 356:2064–2072

    Article  PubMed  CAS  Google Scholar 

  21. Pai HH, Thornton A, Katznelson L et al (2001) Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 49:1079–1092

    Article  PubMed  CAS  Google Scholar 

  22. Brabant G, Poll EM, Jönsson P et al (2009) Etiology, baseline characteristics, and biochemical diagnosis of GH deficiency in the adult: are there regional variations? Eur J Endocrinol 161(Suppl 1):S25–S31

    Article  PubMed  CAS  Google Scholar 

  23. Feldt S, Schüssel K, Quinzler R et al (2012) Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 48:974–981

    Article  PubMed  CAS  Google Scholar 

  24. Wallace WH, Shalet SM, Crowne EC et al (1989) Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1:75–79

    Google Scholar 

  25. Koyama H, Wada T, Nishizawa Y et al (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403–1409

    Article  PubMed  CAS  Google Scholar 

  26. Green DM, Kawashima T, Stovall M et al (2009) Fertility of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 27:2677–2685

    Article  PubMed  CAS  Google Scholar 

  27. Lee SJ, Schover LR, Partridge AH et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931

    Article  PubMed  Google Scholar 

  28. Rowley MJ, Leach DR, Warner GA, Heller CG (1974) Effect of graded doses of ionizing radiation on the human testis. Radiat Res 59:665–678

    Article  PubMed  CAS  Google Scholar 

  29. Georgiou KR, Scherer MA, Fan CM et al (2011) Methotrexate chemotherapy reduces osteogenesis but increases adipogenesis potential in the bone marrow. J Cell Physiol

  30. Wagner LM, Neel MD, Pappo AS et al (2001) Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol 23:568–571

    Article  PubMed  CAS  Google Scholar 

  31. Einenauer DA, Bredenfeld H, Haverkamp H et al (2009) Hodgkin’s lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J Clin Oncol 27:6079–6085

    Article  Google Scholar 

  32. Green DM, Hyland A, Barcos MP et al (2000) Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 18:1492–1499

    PubMed  CAS  Google Scholar 

  33. Majhail NS (2011) Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol 154:301–310

    Article  PubMed  Google Scholar 

  34. Bari A, Marcheselli L, Marcheselli R et al (2011) Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. Mediterr J Hematol Infect Dis 3:e2011065

    Article  PubMed  Google Scholar 

  35. Le Deley M-C, Suzan F, Butull B et al (2007) Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25:292–300

    Article  Google Scholar 

  36. Josting A, Wiedemann S, Franklin J et al (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3440–3446

    Article  PubMed  Google Scholar 

  37. Kalaycio M, Rybicki L, Pohlman B et al (2006) Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604–3610

    Article  PubMed  Google Scholar 

  38. Klimek VM (2013) Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 20:137–143

    Article  PubMed  CAS  Google Scholar 

  39. Schmiegelow K, Levinsen MF, Attarbaschi A et al (2013) Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 31:2469–2476

    Article  PubMed  CAS  Google Scholar 

  40. Longhi A, Ferrari S, Tamburini A et al (2012) Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983–2006). Cancer 118:5050–5059. doi:10.1002/cncr.27493 (Epub 2012 Mar 13. PubMed PMID: 22415578)

    Article  PubMed  Google Scholar 

  41. Bartkowiak D, Humble N, Suhr P et al (2012) Second cancer after radiotherapy, 1981–2007. Radiother Oncol 105:122–126. doi:10.1016/j.radonc.2011.09.013 (Epub 2011 Oct 10. PubMed PMID: 21993405)

    Article  PubMed  Google Scholar 

  42. Landier W, Bathia S (2008) Cancer survivorship: a pediatric perspective. Oncologist 13:1181–1192

    Article  PubMed  Google Scholar 

  43. Marees T, Moll AC, Imhof SM et al (2008) Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100:1771–1779

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. H. Biersack und G. Brabant geben an, dass kein Interessenkonflikt besteht. Das vorliegende Manuskript enthält keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Bereich Hämatologie und Onkologie, Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland

    H. Biersack

  2. Experimentelle und Klinische Endokrinologie, Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland

    G. Brabant

Authors
  1. H. Biersack
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Brabant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Biersack.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biersack, H., Brabant, G. Spätfolgen onkologischer Therapie. Internist 54, 1221–1232 (2013). https://doi.org/10.1007/s00108-013-3355-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-013-3355-z

Schlüsselwörter

Keywords

Search

Navigation